Get the Weekly Intelligence Brief — top committee picks every Sunday.
JAZZ · NASDAQ · STOCK

Jazz Pharmaceuticals (JAZZ) Stock Analysis

Healthcare Updated September 06, 2026
$246.94
52W $123.88 – $266.38
60/100
$15.50B
16.2
0.32
AI Committee Verdict
Buy
60/100
Conviction: Moderate · 60% agreement · 5 analysts
-10.6%
Moderate

Is JAZZ Bullish or Bearish?

Bullish. Innellis AI committee rates Jazz Pharmaceuticals (JAZZ) Buy with a composite score of 60/100 , based on 5 analysts with 60% agreement. Last updated September 06, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +15.17 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -4.83 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

Positive signals support the current rating — vix regime is low -- calm backdrop supports risk-taking. The committee sees sufficient evidence to maintain the constructive view.

Bull & Bear Case

Bull Case
  • ROE of 21.4% shows genuine earnings power backing the valuation — Value
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
  • MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of September 06, 2026
Overall Committee Score
60/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 54%
of 192 Healthcare peers
Value Analyst bullish
63 / 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
+ ROE of 21.4% shows genuine earnings power backing the valuation
Growth Analyst neutral
50 / 100 · Moderate confidence
Moderate growth -- present but not remarkable
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst neutral
48 / 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Macro Analyst bullish
80 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst neutral
58 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2704.43)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 59.8 to 59.8.

Comparing 2026-09-05 to 2026-09-06 (1 day apart).

Technical Analysis

RSI (14)
45.7
Neutral
MACD Histogram
-0.909
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.34
Inside Bands
Price vs Moving Averages
EMA 9
$248.13 Below
EMA 21
$249.46 Below
EMA 50
$246.03 Above
EMA 200
$209.61 Above

Fundamental Analysis

Valuation
89
Growth
59
Profitability
50
Financial Health
80
Cash Flow
70
Valuation
P/E Ratio 16.2×
P/B Ratio 3.25×
PEG Ratio 0.00
Dividend Yield 0.00%
52W High $266.38
52W Low $123.88
Quality & Growth
ROE -824.7%
ROA -305.5%
Gross Margin 8467.4%
Operating Margin 3105.1%
Revenue Growth YoY
Debt / Equity 0.92
AI Fundamental Assessment
P/E ratio of 16.2 (inexpensive relative to a 15-40x range); Price-to-book of 3.2x; PEG ratio of 0.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -8.2%; Return on assets of -3.1%; Net margin of 20.4%; Gross margin of 84.7%; Current ratio of 1.78 (healthy short-term liquidity); Debt-to-equity of 0.92; Free cash flow per share is positive (24.40); Most recent quarter missed estimates by 9.4%; EPS growth decelerating (-4.5% -> -9.9% QoQ); Average YoY EPS growth of 169.2%; Analyst estimates falling over recent quarters
Get the Full JAZZ Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime